Known for Crohn's: TiGenix files for a $58 million IPO

TiGenix, which is developing injectable stem cell therapies for the treatment of perianal fistulas, filed on Tuesday with the SEC to raise up to $58 million in an initial public offering. 


 The Leuven, Belgium-based company, which was founded in 2000 and booked $8 million in sales for the 12 months ended June 30, 2015, plans to list on the Nasdaq under the symbol TIG. Canaccord Genuity and Nomura Securities are the joint bookrunners on the deal. No pricing terms were disclosed.

Share on Google Plus

About Jessica Hornberger

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.